Company intelligence / Profile preview

In-Altum

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~25
Development stage: Other

Overview

The lead drug candidate for HPV-related low grade cervical intraepithelial neoplasia has completed successful Phase 2 trials, demonstrating safety, tolerability, and potential efficacy. Data have been presented to health authorities with positive feedback from end-of-phase meetings with FDA and EMA. Additional programs are in preclinical or early clinical stages targeting viral infections including COVID‑19 using interferon-based approaches.

Therapeutic areas: ImmunologyInfectious DiseasesOncologyWomen's Health
Modalities: Small moleculeProtein (Interferon-based therapies)
Industry: Biotech

Partnerships

European investor group for financing commitment

Beyond the preview

Go deeper on In-Altum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on In-Altum.

Explore the full profile